Alps Advisors Inc. Acquires 82,455 Shares of Abbott Laboratories $ABT

Alps Advisors Inc. increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 76.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 190,327 shares of the healthcare product maker’s stock after purchasing an additional 82,455 shares during the quarter. Alps Advisors Inc.’s holdings in Abbott Laboratories were worth $25,492,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. IMG Wealth Management Inc. raised its stake in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the period. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories in the 3rd quarter valued at $31,000. Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in Abbott Laboratories during the second quarter worth $32,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.6%

Shares of Abbott Laboratories stock opened at $110.86 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The company has a market capitalization of $192.77 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 1.76 and a beta of 0.75. The firm’s 50-day moving average price is $120.86 and its two-hundred day moving average price is $126.90.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the business posted $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a $0.63 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings downgraded Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Raymond James Financial decreased their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group lowered their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. BTIG Research reduced their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.